Trial Profile
A Phase 1 Study of E7090 in Subjects With Solid Tumor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 May 2022
Price :
$35
*
At a glance
- Drugs Tasurgratinib (Primary)
- Indications Cholangiocarcinoma; Endometrial cancer; Gastric cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Eisai Co Ltd
- 23 Sep 2021 Status changed from active, no longer recruiting to completed.
- 02 Sep 2021 Planned End Date changed from 1 Sep 2021 to 30 Sep 2021.
- 02 Sep 2021 Planned primary completion date changed from 1 Sep 2021 to 30 Sep 2021.